This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing AI use in drug discovery and development
Ticker(s): IBBWho's the expert?
Institution: IQVIA Inc.
- Has been in global pharma and medtech consulting for last 4 years. Working with all major firms and their digital transformation and AI/ML strategies. Before that worked in the industry with large players like GSK and Novartis for over 20 years.
- Entrepreneurial global leader, high-energy business innovator, risk-taker and goal driven executive with 20+ years of experience inspiring teams & delivering winning portfolios through differentiated insights, data, digital analytics and tech driven healthcare solutions. Delivered both shareholder value & improved business results while continuing to delight our consumers, shoppers & customers.
Interview GoalThis interview will focus on how AI is impacting drug discovery/development now and outlook for the future, emerging AI leaders among biotech/pharma co.'s, AI vendors, other groups (like CROs) using AI in drug discovery/development
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
